Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIT-013 proof-of-concept trial in moderately active rheumatoid arthritis
NL-OMON58806Phase 2Completed
- Sponsor
- Citryll
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CIT013 in rheumatoid arthritis (RA) (3 arms), sponsored by Citryll. Primary endpoint: Mean change in DAS28-CRP at Day 43 pooled CIT-013 versus placebo. Started Aug 2025; status: completed.
02
Drugs
CIT013
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON58806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58806.